Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Feb;35(2):251-9.
doi: 10.1007/s10096-015-2538-z. Epub 2015 Dec 12.

The impact of the introduction of fidaxomicin on the management of Clostridium difficile infection in seven NHS secondary care hospitals in England: a series of local service evaluations

Affiliations

The impact of the introduction of fidaxomicin on the management of Clostridium difficile infection in seven NHS secondary care hospitals in England: a series of local service evaluations

S D Goldenberg et al. Eur J Clin Microbiol Infect Dis. 2016 Feb.

Abstract

Clostridium difficile infection (CDI) is associated with high mortality. Reducing incidence is a priority for patients, clinicians, the National Health Service (NHS) and Public Health England alike. In June 2012, fidaxomicin (FDX) was launched for the treatment of adults with CDI. The objective of this evaluation was to collect robust real-world data to understand the effectiveness of FDX in routine practice. In seven hospitals introducing FDX between July 2012 and July 2013, data were collected retrospectively from medical records on CDI episodes occurring 12 months before/after the introduction of FDX. All hospitalised patients aged ≥18 years with primary CDI (diarrhoea with presence of toxin A/B without a previous CDI in the previous 3 months) were included. Recurrence was defined as in-patient diarrhoea re-emergence requiring treatment any time within 3 months after the first episode. Each hospital had a different protocol for the use of FDX. In hospitals A and B, where FDX was used first line for all primary and recurrent episodes, the recurrence rate reduced from 10.6 % to 3.1 % and from 16.3 % to 3.1 %, with a significant difference in 28-day mortality from 18.2 % to 3.1 % (p < 0.05) and 17.3 % to 6.3 % (p < 0.05) for hospitals A and B, respectively. In hospitals using FDX in selected patients only, the changes in recurrence rates and mortality were less marked. The pattern of adoption of FDX appears to affect its impact on CDI outcome, with maximum reduction in recurrence and all-cause mortality where it is used as first-line treatment.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Service evaluation design showing two retrospective observation periods, before (pre) and after (post) introduction of fidaxomicin (FDX)
Fig. 2
Fig. 2
Clostridium difficile infection (CDI) recurrence rates in the pre- and post-FDX observation periods at participating hospitals

References

    1. Aguado JM, Anttila VJ, Galperine T, CDI Consensus Consortium et al. Highlighting clinical needs in Clostridium difficile infection: the views of European healthcare professionals at the front line. J Hosp Infect. 2015;90:117–125. doi: 10.1016/j.jhin.2015.03.001. - DOI - PubMed
    1. Forster AJ, Taljaard M, Oake N, Wilson K, Roth V, van Walraven C. The effect of hospital-acquired infection with Clostridium difficile on length of stay in hospital. CMAJ. 2012;184:37–42. doi: 10.1503/cmaj.110543. - DOI - PMC - PubMed
    1. van Kleef E, Green N, Goldenberg SD, et al. Excess length of stay and mortality due to Clostridium difficile infection: a multi-state modelling approach. J Hosp Infect. 2014;88:213–217. doi: 10.1016/j.jhin.2014.08.008. - DOI - PubMed
    1. Murphy CR, Avery TR, Dubberke ER, Huang SS. Frequent hospital readmissions for Clostridium difficile infection and the impact on estimates of hospital-associated C. difficile burden. Infect Control Hosp Epidemiol. 2012;33:20–28. doi: 10.1086/663209. - DOI - PMC - PubMed
    1. Zilberberg MD, Shorr AF, Micek ST, Kollef MH. Clostridium difficile recurrence is a strong predictor of 30-day rehospitalization among patients in intensive care. Infect Control Hosp Epidemiol. 2015;36:273–279. doi: 10.1017/ice.2014.47. - DOI - PubMed

Publication types

MeSH terms